Cutaneous Leishmaniasis in Patients under Biologic Therapies: A Spanish CLINI-AEDV Multicentre Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ciudad Andrea, Pujol Ramón M, Gallardo Fernándo, Lasheras-Pérez Miguel Antonio, Botella Estrada Rafael, Armengot-Carbó Miquel, Fernández Tapia Verónica, Mas Matas Bernat, Solá-Truyols Amador, Aguado Vázquez Álvaro, Ballester Nortes Irene, Llamas-Velasco Mar, Esquius Rafat Mireia, Fuertes Irene, Masferrer Emili, Roé Crespo Esther, De la Vega-Ruiz Diego, Rocamora Durán Vicenç, Imbernón-Moya Adrián, Blanes Martínez María Del Mar, Garbayo-Salmons Patricia, Alonso Naranjo Laura, Mercader-García Pedro, Expósito-Serrano Vicente, Pesqué David, Descalzo Miguel Angel, García-Doval Ignacio, Martín-Ezquerra Gemma
Аннотация
Anti-TNFα agents have been associated with the reactivation of granulomatous infections, including leishmaniasis. Cases of atypical or recurrent cutaneous (CL) or mucocutaneous leishmaniasis (MCL) have been reported in patients on biologics. We conducted a retrospective analysis of a multicenter database to describe the clinical characteristics and management of CL and MCL in patients receiving biological therapy in an endemic area. Clinical features, diagnostics, therapies, and outcomes were analyzed. Seventy-one patients were included (63 CL and 8 MCL). The most common underlying condition was inflammatory bowel disease (33.8%). Lesions were multifocal in 40% and larger than 1 cm in 94.4%. Treatment failures were more frequent in MCL (50%) than CL (8.1%). Biologic therapy was discontinued in 53.5%, leading to worsening of the underlying disease in 44.7%. No significant difference in cure rates was observed between patients who continued vs. discontinued biologics (p=0.868). These findings highlight the clinical burden of CL and MCL in patients undergoing anti-TNFα therapy and suggest that discontinuation of biologic therapy did not significantly impact cure rates, emphasizing the need for standardized strategies balancing infection control and underlying inflammatory disease management.